Holen Sie sich die Stockscreener-App
63.61
1.90%
-1.23
Handel nachbörslich:
63.99
0.38
+0.60%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$64.84
Offen:
$64.56
24-Stunden-Volumen:
9.34M
Relative Volume:
0.83
Marktkapitalisierung:
$129.90B
Einnahmen:
$48.48B
Nettoeinkommen (Verlust:
$7.27B
KGV:
17.85
EPS:
3.5626
Netto-Cashflow:
$11.91B
1W Leistung:
-3.46%
1M Leistung:
+10.47%
6M Leistung:
+6.14%
1J Leistung:
+38.49%
1-Tages-Spanne:
$63.54
$65.02
1-Wochen-Bereich:
$63.20
$65.41
52-Wochen-Spanne:
$42.52
$68.10
Bristol Myers Squibb Co Stock (BMY) Company Profile
Firmenname
Bristol Myers Squibb Co
Sektor
Telefon
(609) 252-4621
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
63.61 | 127.75B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
1,215.02 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
259.80 | 640.91B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
250.09 | 453.91B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
130.42 | 322.95B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
154.61 | 296.72B | 54.66B | 13.58B | 16.05B | 7.0171 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-01-07 | Hochstufung | UBS | Neutral → Buy |
| 2025-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-12-12 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-08-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2024-12-16 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-13 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-07-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2024-02-06 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-10 | Eingeleitet | SVB Securities | Market Perform |
| 2023-06-28 | Eingeleitet | Daiwa Securities | Outperform |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-01-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Eingeleitet | Credit Suisse | Neutral |
| 2022-10-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-06-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Underweight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-01 | Herabstufung | Argus | Buy → Hold |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Hochstufung | Truist | Hold → Buy |
| 2020-11-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-11-06 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-07-28 | Eingeleitet | Raymond James | Outperform |
| 2020-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-06 | Fortgesetzt | Citigroup | Buy |
| 2019-12-13 | Hochstufung | Argus | Hold → Buy |
| 2019-11-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-08-14 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-05-20 | Herabstufung | Argus | Buy → Hold |
| 2019-05-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Fortgesetzt | JP Morgan | Overweight |
| 2019-01-15 | Hochstufung | Societe Generale | Sell → Buy |
| 2018-10-22 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
New Iza-bren Approvals Underscore China's Rising Role In Bispecific ADCs - Benzinga
Legal intelligence start-up Theo Ai appoints former Bristol Myers Squibb GC to board of directors - The Global Legal Post
Bristol-Myers Squibb stock rating held at Market Perform by Raymond James - Investing.com
Should You Buy, Hold, or Sell BMY Stock Ahead of Q2 Earnings? - TradingView
Theo Ai Appoints Ex-Bristol Myers Squibb GC To Board - Law360
Theo Ai Appoints Former Bristol Myers Squibb General Counsel Sandra Leung to Board - citybiz
Bristol-Myers Squibb stock hits 52-week high at 62.89 USD - Investing.com
BMO reiterates Bristol-Myers Squibb stock rating on Cobenfy edge - Investing.com
BMO reiterates Bristol-Myers Squibb stock rating on Cobenfy edge By Investing.com - Investing.com India
Theo Ai Appoints Former Bristol Myers Squibb General Counsel Sandra Leung to Board of Directors - citybiz
Bristol Myers Squibb stock holds gains as Takeda partnership and Revlimid erosion shape outlook - Ad-hoc-news.de
Theo Ai Bolsters Leadership, Appoints Sandra Leung, Former Bristol Myers Squibb General Counsel, to Board of Directors - PR Newswire
BMS launches dual immunotherapy for metastatic melanoma - The Hindu
Bristol Myers Squibb stock reacts to latest Opdivo data and solid 2024 outlook - Ad-hoc-news.de
BMY|Bristol-Myers Squibb Co|Price:62.090|Chg%:+0.580 - TradingKey
Bristol Myers Squibb stock trades steadily as Eliquis and Opdivo anchor earnings and guidance - Ad-hoc-news.de
Why is Barclays Bullish on Bristol-Myers Squibb (BMY) Now - Kavout | AI
Bristol Myers Squibb stock reacts as cancer and cardiovascular pipeline updates follow recent earnin - Ad-hoc-news.de
Bristol-Myers Squibb Co (BMY) Income Statement - TradingKey
Bristol-Myers Squibb Co (BMY) Cash Flow - TradingKey
Bristol-Myers Squibb’s High Dividend Temporarily Backed by Financial Support, but Patent Cliff Poses Future Concerns - NAI500
Is Bristol Myers Squibb's Dividend Too Good to Be True? Here's My Honest Answer - The Motley Fool
Is Bristol Myers Squibb's Dividend Too Good to Be True? Here's My Honest Answer - The Motley Fool
Bristol-Myers Squibb Co (BMY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bristol-Myers Squibb Co (BMY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bristol-Myers Squibb Company (BRM.F) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
BMY|Bristol-Myers Squibb Co|Price:62.560|Chg%:+0.470 - TradingKey
Bristol-Myers Squibb stock trades steady as Opdivo and Eliquis underpin revenue and margins - Ad-hoc-news.de
Bristol Myers Squibb stock steadies as investors weigh Karuna buyout and latest oncology data - AD HOC NEWS
Oak Associates Ltd. OH Acquires New Position in Bristol Myers Squibb Company $BMY - MarketBeat
Public Employees Retirement System of Ohio Has $51.79 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
Why Investors Are Watching Bristol Myers Squibb, Gilead Sciences and Amgen - Kalkine Media
Bristol Myers Squibb Company $BMY Stake Raised by Sei Investments Co. - MarketBeat
Why Is Bristol Myers Squibb (NYSE:BMY) On S&P 500 Radar? - Kalkine Media
Compound Planning Inc. Has $4.94 Million Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Arrowstreet Capital Limited Partnership Has $538.13 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb Co (BMY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bristol Myers Squibb stock trades steady as cardiovascular and oncology pipeline shapes outlook - AD HOC NEWS
Bristol-Myers Squibb Company (BMY) Options Chain - Yahoo! Finance Canada
Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
DOL Brief Sides With Bristol-Myers in PRT Appeal - planadviser
Bristol Myers Squibb stock steadies as investors weigh Revlimid erosion against new product launches - AD HOC NEWS
DOL Anchors Wave of Briefs Backing Bristol-Myers in PRT Appeal - plansponsor
DOL Takes Swipe At Derisking Cases In Bristol-Myers Brief - Law360
Bristol Myers Squibb stock stabilizes as Eliquis and Opdivo help offset Revlimid erosion - AD HOC NEWS
Donald TrumpBRISTOL MYERS SQUIBB CO Trump Trade on May. 18, 2026 - Quiver Quantitative
Bristol Myers Squibb stock steadies as Eliquis and Opdivo shape earnings outlook - AD HOC NEWS
Bristol Myers Squibb (BMY) Wins FDA Filing And Nvidia Tie Up, Is It Still Undervalued? - simplywall.st
Alexandria Real Estate Equities (ARE) Delivers 427,000 RSF Bristol Myers Squibb R And D Hub - Yahoo Finance Singapore
Bristol Myers Squibb stock edges higher as recent results and oncology portfolio shape investor view - AD HOC NEWS
Bristol Myers Squibb Partners With NVIDIA to Build Pharma's Largest Supercomputer - Mjengo Hub
Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Bristol Myers Squibb Co-Aktie (BMY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Gallman Cari | EVP, General Counsel |
Aug 01 '26 |
Option Exercise |
0.00 |
1,061 |
0 |
14,192 |
| Haller Julia A | Director |
Jun 15 '26 |
Option Exercise |
53.76 |
20,460 |
1,099,930 |
34,079 |
| Short Bartie Wendy | EVP, Corporate Affairs |
Jun 03 '26 |
Option Exercise |
0.00 |
8,040 |
0 |
15,957 |
| Lenkowsky Adam | EVP, Chief Commercial Officer |
May 01 '26 |
Option Exercise |
0.00 |
1,373 |
0 |
20,508 |
| Shanahan Karin | EVP, Chief Supply Chain & Ops |
Apr 01 '26 |
Option Exercise |
0.00 |
3,307 |
0 |
27,580 |
| Elkins David V | EVP, Chief Financial Officer |
Apr 01 '26 |
Sale |
61.67 |
30,000 |
1,850,016 |
159,248 |
1.59%
2.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):